Pharma has the podium as Novo and Lilly stop talking about GLP-1 longevity and start measuring it, bringing early aging data ...

At ARDD 2026, senior FDA officials sketch how a therapy targeting aging might one day reach approval, revealing that ...

Zsolt Farkas of Evolut on why today's longevity valuations only work if the winners spend the next decade buying everything ...

13th Aging Research and Drug Discovery meeting opened with a pitch for prevention and a program building the endpoints the field needs. A quick spin through the attendee list is enough to show where ...

One-year results for the open-chest version look promising, the company says, and a catheter-based method is now enrolling ...

A further $173 billion a year is real on paper – but only once three separate regulatory clocks finish running down.

Amorepacific deal puts therapeutic target discovery to work on skin aging – and Junevity sees scope for an ‘Ozempic moment’.

Younger founder Christin Glorioso on turning a six-month competition into a side-by-side trial of aging clocks.

LW-1017, an oral drug that switches the brain’s cleanup system back on, reduced Parkinson’s and Alzheimer’s pathology in aged ...

Basecamp Research will train AI models on the world’s largest biological dataset and design new medicines. Most AI ...